Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis

Transplantation and Cellular Therapy(2022)10.1016/j.jtct.2022.07.013Source: DataRank Database

Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis is a research paper published in Transplantation and Cellular Therapy (2022). On theSindex it has a DataRank of 0. It has been cited 32 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access32 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (31 grants)Impact (FWCI 4.28)OA: hybridTopics (36)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (42)

Amin M. Alousi ORCID,Joseph Pidala,Mukta Arora ORCID,Stephen R. Spellman ORCID,Michael Hemmer

Live enrichment

PubMed:35853610 PMC:PMC10141544 OpenAlex:https://openalex.org/W4285679625

Office of Naval Research

Grant: N00014-20-1-2705

National Institute of Allergy and Infectious Diseases

Grant: HHSH250201700006C

National Institute of Allergy and Infectious Diseases

Grant: U24CA076518

Health Resources and Services Administration

Grant: N00014-20-1-2832

NCI NIH HHS

Grant: P30 CA008748

National Institutes of Health

Grant: 2U24CA076518-16

A Data Resource for Analyzing Blood and Marrow Transplants

Astellas Pharma US

Legend Biotech

Celgene

Fuji Pharma

Janssen Pharmaceuticals

Kyowa Kirin Pharmaceutical Development

National Institutes of Health

Merck

National Cancer Institute

U.S. Public Health Service

Daiichi Sankyo Europe

Daiichi-Sankyo

Sanofi

CytoSen Therapeutics

Merck Sharp and Dohme

Pfizer

Bristol-Myers Squibb

Defense Systems Management College

Incyte

National Heart, Lung, and Blood Institute

Nippon Shinyaku

Novartis

CareDx

Cidara Therapeutics

Medical College of Wisconsin

FWCI

4.28

Citation Percentile

1.0%

Citation Trend

2022

2023

2024

2025

2026

hybridLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.jtct.2022.07.013

publisherhttps://doi.org/10.1016/j.jtct.2022.07.013

publisherhttps://api.elsevier.com/content/article/PII:S2666636722014762?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2666636722014762?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35853610

Fields of Study

Hematopoietic Stem Cell TransplantationPolyomavirus and related diseasesRenal Transplantation Outcomes and Treatments03 medical and health sciences0302 clinical medicine

MeSH Terms

Antilymphocyte SerumCyclophosphamideFemaleGraft vs Host DiseaseHumansMaleRetrospective StudiesHematopoietic Stem Cell Transplantation

Keywords

MedicineGraft-versus-host diseaseInternal medicineTransplantationGastroenterologyCyclophosphamideHazard ratioRetrospective cohort studyImmunologySurgeryChemotherapyConfidence intervalProphylaxisNon-relapse MortalityPost-transplantation CyclophosphamideMaleHematopoietic Stem Cell Transplantation610Graft vs Host DiseaseHumansFemaleAntilymphocyte SerumRetrospective Studies

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being